Triastek’s 3D-printed D23 tablet shows strong clinical results for IgAN treatment
Triastek has reported promising clinical results for its 3D-printed drug delivery product, D23 (Budesonide Ileum Targeted Tablets), which is being developed for the treatment of ... Read More
Calliditas Therapeutics bags TARPEYO FDA approval for IgAN
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) has announced a landmark FDA approval for TARPEYO (budesonide) delayed release capsules, aimed at reducing kidney function ... Read More